Screening for Latent Infectious Disease in Patients with Alopecia Areata Before Initiating JAK Inhibitors Therapy: A Single-Center Real-World Retrospective Study

    October 2023 in “ Frontiers in medicine
    Jundong Huang, Zhi‐Rong Tan, Yan Tang, Wei Shi
    Image of study
    TLDR Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.
    This study analyzed pre-treatment screening data for 218 alopecia areata patients before initiating Janus kinase (JAK) inhibitors. Of these, 163 patients (74.8%) began JAK inhibitor therapy. Screening revealed 32 patients positive for antinuclear antibodies, 10 for hepatitis B surface antigen, 3 for treponema pallidum hemagglutination assay, 9 for thyroid-stimulating hormone abnormalities, and 37 for tuberculosis indicators. No patients tested positive for hepatitis C or HIV. The findings underscore the importance of comprehensive screening for latent infections, particularly tuberculosis and hepatitis B, to ensure the safe use of JAK inhibitors in treating alopecia areata.
    Discuss this study in the Community →

    Cited in this study

    10 / 10 results

    Related

    1 / 1 results